A chimeric IgG1 anti-GD2 monoclonal antibody immunotherapy (brand: Qarziba) used as maintenance after response in relapsed/refractory high‑grade osteosarcoma. It binds the disialoganglioside GD2 on tumor cells and triggers immune effector killing via Fc-mediated ADCC and phagocytosis, and complement‑dependent cytotoxicity (CDC). Dosed as continuous IV 14 mg/m2/day on days 1–5 every 28 days for 5 cycles.
Chimeric IgG1 anti-GD2 monoclonal antibody that binds GD2 on tumor cells and elicits immune effector killing via Fcγ receptor–mediated ADCC and phagocytosis, and complement-dependent cytotoxicity (CDC).
YES
DIRECT
Anti-GD2 IgG1 binds GD2 on target cells and recruits immune effectors to kill via FcγR-mediated ADCC and phagocytosis, and complement-dependent cytotoxicity (CDC).
A chimeric IgG1 anti-GD2 monoclonal antibody immunotherapy (brand: Qarziba) used as maintenance after response in relapsed/refractory high‑grade osteosarcoma. It binds the disialoganglioside GD2 on tumor cells and triggers immune effector killing via Fc-mediated ADCC and phagocytosis, and complement‑dependent cytotoxicity (CDC). Dosed as continuous IV 14 mg/m2/day on days 1–5 every 28 days for 5 cycles.
Chimeric IgG1 anti-GD2 monoclonal antibody that binds GD2 on tumor cells and elicits immune effector killing via Fcγ receptor–mediated ADCC and phagocytosis, and complement-dependent cytotoxicity (CDC).
NO
INDIRECT
The antibody binds GD2 on tumor cells; its Fc engages FCGR3A (CD16a) on NK/myeloid cells to drive ADCC and phagocytosis, and activates complement (CDC), killing GD2+ cells rather than FCGR3A+ cells.
Polyclonal antibody preparation that depletes T lymphocytes for induction immunosuppression.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity and Fc-mediated ADCC, with additional T-cell apoptosis and functional inhibition, producing potent immunosuppression.
YES
DIRECT
ATG binds CD28 on T cells and depletes them via complement-dependent cytotoxicity and Fc-mediated ADCC, with additional apoptosis induction.
A chimeric IgG1 anti-GD2 monoclonal antibody immunotherapy (brand: Qarziba) used as maintenance after response in relapsed/refractory high‑grade osteosarcoma. It binds the disialoganglioside GD2 on tumor cells and triggers immune effector killing via Fc-mediated ADCC and phagocytosis, and complement‑dependent cytotoxicity (CDC). Dosed as continuous IV 14 mg/m2/day on days 1–5 every 28 days for 5 cycles.
Chimeric IgG1 anti-GD2 monoclonal antibody that binds GD2 on tumor cells and elicits immune effector killing via Fcγ receptor–mediated ADCC and phagocytosis, and complement-dependent cytotoxicity (CDC).
NO
INDIRECT
Dinutuximab beta binds GD2 on tumor cells; its Fc engages FCGR2A (CD32a) on immune effector cells to drive ADCC/phagocytosis and CDC against GD2+ targets. FCGR2A-expressing cells are not killed by the drug.
A chimeric IgG1 anti-GD2 monoclonal antibody immunotherapy (brand: Qarziba) used as maintenance after response in relapsed/refractory high‑grade osteosarcoma. It binds the disialoganglioside GD2 on tumor cells and triggers immune effector killing via Fc-mediated ADCC and phagocytosis, and complement‑dependent cytotoxicity (CDC). Dosed as continuous IV 14 mg/m2/day on days 1–5 every 28 days for 5 cycles.
Chimeric IgG1 anti-GD2 monoclonal antibody that binds GD2 on tumor cells and elicits immune effector killing via Fcγ receptor–mediated ADCC and phagocytosis, and complement-dependent cytotoxicity (CDC).
NO
INDIRECT
The antibody binds GD2 on tumor cells and engages CD64 (FCGR1A) on immune effector cells via its Fc to trigger ADCC/ADCP and complement killing of GD2+ cells; CD64-expressing cells are not directly targeted or killed.